Multivalent Polymer-Peptide Conjugates: A General Platform for Inhibiting Amyloid Beta Peptide Aggregation

Xing Jiang, Abigail J. Halmes, Giuseppe Licari, John W. Smith, Yang Song, Edwin G. Moore, Qian Chen, Emad Tajkhorshid, Chad M. Rienstra, Jeffrey S. Moore

Research output: Contribution to journalArticle

Abstract

Protein aggregation is implicated in multiple deposition diseases including Alzheimer's Disease, which features the formation of toxic aggregates of amyloid beta (Aβ) peptides. Many inhibitors have been developed to impede or reverse Aβ aggregation. Multivalent inhibitors, however, have been largely overlooked despite the promise of high inhibition efficiency endowed by the multivalent nature of Aβ aggregates. In this work, we report the success of multivalent polymer-peptide conjugates (mPPCs) as a general class of inhibitors of the aggregation of Aβ40. Significantly delayed onset of fibril formation was realized using mPPCs prepared with three peptide/peptoid ligands covering a range of polymer molecular weights (MWs) and ligand loadings. Dose dependence studies showed that the nature of the ligands is a key factor in mPPC inhibition potency. The negatively charged ligand LPFFD leads to more efficient mPPCs compared to mPPCs with the neutral ligands, and is most effective at 7% ligand loading across different MWs. Molecular dynamics simulations along with dynamic light scattering experiments suggestâ»that mPPCs form globular structures in solution due to ligand-ligand interactions. Such interactions are key to the spatial proximity of ligands and thus to the multivalency effect of mPPC inhibition. Excess ligand-ligand interactions, however, reduce the accessibility of mPPC ligands to Aβ peptides, and impair the overall inhibition potency.

Original languageEnglish (US)
Pages (from-to)1365-1371
Number of pages7
JournalACS Macro Letters
Volume8
Issue number10
DOIs
StatePublished - Oct 15 2019

Fingerprint

Amyloid beta-Peptides
Peptides
Polymers
Agglomeration
Ligands
Amyloid
Peptoids
Molecular weight
Poisons
Dynamic light scattering
Molecular dynamics

ASJC Scopus subject areas

  • Organic Chemistry
  • Polymers and Plastics
  • Inorganic Chemistry
  • Materials Chemistry

Cite this

Multivalent Polymer-Peptide Conjugates : A General Platform for Inhibiting Amyloid Beta Peptide Aggregation. / Jiang, Xing; Halmes, Abigail J.; Licari, Giuseppe; Smith, John W.; Song, Yang; Moore, Edwin G.; Chen, Qian; Tajkhorshid, Emad; Rienstra, Chad M.; Moore, Jeffrey S.

In: ACS Macro Letters, Vol. 8, No. 10, 15.10.2019, p. 1365-1371.

Research output: Contribution to journalArticle

Jiang, Xing ; Halmes, Abigail J. ; Licari, Giuseppe ; Smith, John W. ; Song, Yang ; Moore, Edwin G. ; Chen, Qian ; Tajkhorshid, Emad ; Rienstra, Chad M. ; Moore, Jeffrey S. / Multivalent Polymer-Peptide Conjugates : A General Platform for Inhibiting Amyloid Beta Peptide Aggregation. In: ACS Macro Letters. 2019 ; Vol. 8, No. 10. pp. 1365-1371.
@article{ccdaac0977494644996472bffdb36ee0,
title = "Multivalent Polymer-Peptide Conjugates: A General Platform for Inhibiting Amyloid Beta Peptide Aggregation",
abstract = "Protein aggregation is implicated in multiple deposition diseases including Alzheimer's Disease, which features the formation of toxic aggregates of amyloid beta (Aβ) peptides. Many inhibitors have been developed to impede or reverse Aβ aggregation. Multivalent inhibitors, however, have been largely overlooked despite the promise of high inhibition efficiency endowed by the multivalent nature of Aβ aggregates. In this work, we report the success of multivalent polymer-peptide conjugates (mPPCs) as a general class of inhibitors of the aggregation of Aβ40. Significantly delayed onset of fibril formation was realized using mPPCs prepared with three peptide/peptoid ligands covering a range of polymer molecular weights (MWs) and ligand loadings. Dose dependence studies showed that the nature of the ligands is a key factor in mPPC inhibition potency. The negatively charged ligand LPFFD leads to more efficient mPPCs compared to mPPCs with the neutral ligands, and is most effective at 7{\%} ligand loading across different MWs. Molecular dynamics simulations along with dynamic light scattering experiments suggest{\^a}»that mPPCs form globular structures in solution due to ligand-ligand interactions. Such interactions are key to the spatial proximity of ligands and thus to the multivalency effect of mPPC inhibition. Excess ligand-ligand interactions, however, reduce the accessibility of mPPC ligands to Aβ peptides, and impair the overall inhibition potency.",
author = "Xing Jiang and Halmes, {Abigail J.} and Giuseppe Licari and Smith, {John W.} and Yang Song and Moore, {Edwin G.} and Qian Chen and Emad Tajkhorshid and Rienstra, {Chad M.} and Moore, {Jeffrey S.}",
year = "2019",
month = "10",
day = "15",
doi = "10.1021/acsmacrolett.9b00559",
language = "English (US)",
volume = "8",
pages = "1365--1371",
journal = "ACS Macro Letters",
issn = "2161-1653",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Multivalent Polymer-Peptide Conjugates

T2 - A General Platform for Inhibiting Amyloid Beta Peptide Aggregation

AU - Jiang, Xing

AU - Halmes, Abigail J.

AU - Licari, Giuseppe

AU - Smith, John W.

AU - Song, Yang

AU - Moore, Edwin G.

AU - Chen, Qian

AU - Tajkhorshid, Emad

AU - Rienstra, Chad M.

AU - Moore, Jeffrey S.

PY - 2019/10/15

Y1 - 2019/10/15

N2 - Protein aggregation is implicated in multiple deposition diseases including Alzheimer's Disease, which features the formation of toxic aggregates of amyloid beta (Aβ) peptides. Many inhibitors have been developed to impede or reverse Aβ aggregation. Multivalent inhibitors, however, have been largely overlooked despite the promise of high inhibition efficiency endowed by the multivalent nature of Aβ aggregates. In this work, we report the success of multivalent polymer-peptide conjugates (mPPCs) as a general class of inhibitors of the aggregation of Aβ40. Significantly delayed onset of fibril formation was realized using mPPCs prepared with three peptide/peptoid ligands covering a range of polymer molecular weights (MWs) and ligand loadings. Dose dependence studies showed that the nature of the ligands is a key factor in mPPC inhibition potency. The negatively charged ligand LPFFD leads to more efficient mPPCs compared to mPPCs with the neutral ligands, and is most effective at 7% ligand loading across different MWs. Molecular dynamics simulations along with dynamic light scattering experiments suggestâ»that mPPCs form globular structures in solution due to ligand-ligand interactions. Such interactions are key to the spatial proximity of ligands and thus to the multivalency effect of mPPC inhibition. Excess ligand-ligand interactions, however, reduce the accessibility of mPPC ligands to Aβ peptides, and impair the overall inhibition potency.

AB - Protein aggregation is implicated in multiple deposition diseases including Alzheimer's Disease, which features the formation of toxic aggregates of amyloid beta (Aβ) peptides. Many inhibitors have been developed to impede or reverse Aβ aggregation. Multivalent inhibitors, however, have been largely overlooked despite the promise of high inhibition efficiency endowed by the multivalent nature of Aβ aggregates. In this work, we report the success of multivalent polymer-peptide conjugates (mPPCs) as a general class of inhibitors of the aggregation of Aβ40. Significantly delayed onset of fibril formation was realized using mPPCs prepared with three peptide/peptoid ligands covering a range of polymer molecular weights (MWs) and ligand loadings. Dose dependence studies showed that the nature of the ligands is a key factor in mPPC inhibition potency. The negatively charged ligand LPFFD leads to more efficient mPPCs compared to mPPCs with the neutral ligands, and is most effective at 7% ligand loading across different MWs. Molecular dynamics simulations along with dynamic light scattering experiments suggestâ»that mPPCs form globular structures in solution due to ligand-ligand interactions. Such interactions are key to the spatial proximity of ligands and thus to the multivalency effect of mPPC inhibition. Excess ligand-ligand interactions, however, reduce the accessibility of mPPC ligands to Aβ peptides, and impair the overall inhibition potency.

UR - http://www.scopus.com/inward/record.url?scp=85073097542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073097542&partnerID=8YFLogxK

U2 - 10.1021/acsmacrolett.9b00559

DO - 10.1021/acsmacrolett.9b00559

M3 - Article

AN - SCOPUS:85073097542

VL - 8

SP - 1365

EP - 1371

JO - ACS Macro Letters

JF - ACS Macro Letters

SN - 2161-1653

IS - 10

ER -